Halozyme Therapeutics (HALO) Operating Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Operating Expenses data on file, last reported at $192.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 55.84% year-over-year to $192.2 million in Q1 2026; TTM through Mar 2026 was $996.5 million, a 104.68% increase from a year earlier, with the FY2025 full-year figure at $927.6 million, up 99.98% from the prior year.
• Operating Expenses for Q1 2026 stood at $192.2 million, down from $544.7 million in the prior quarter.
• Over the last five years, Operating Expenses for HALO reached as high as $544.7 million in Q4 2025 and fell as low as $41.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $145.2 million across 5 years, with a median of $123.3 million in 2025.
• Across the five-year window, Operating Expenses dropped 9.85% in 2024 and soared 344.59% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $107.0 million in 2022, then gained by 20.58% to $129.0 million in 2023, then dropped by 5.04% to $122.5 million in 2024, then jumped by 344.59% to $544.7 million in 2025, then plunged by 64.71% to $192.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $192.2 million in Q1 2026, $544.7 million in Q4 2025, and $136.3 million in Q3 2025.